

Imidazoline Receptor

Imidazoline receptors are the primary receptors on which clonidine and other imidazolines act. There are three classes of imidazoline receptors: I1 receptor – mediates the sympatho-inhibitory actions of imidazolines to lower blood pressure, (NISCH or IRAS, imidazoline receptor antisera selected), I2 receptor - an allosteric binding site of monoamine oxidase and is involved in pain modulation and neuroprotection, I3 receptor - regulates insulin secretion from pancreatic beta cells. Activated I1-imidazoline receptors trigger the hydrolysis of phosphatidylcholine into DAG. Elevated DAG levels in turn trigger the synthesis of second messengers arachidonic acid and downstreameicosanoids. In addition, the sodium-hydrogen antiporter is inhibited, and enzymes of catecholamine synthesis are induced. The I1-imidazoline receptor may belong to the neurocytokine receptorfamily, since its signaling pathways are similar to those of interleukins.

Imidazoline Receptor Inhibitors, Agonists & Antagonists

Agmatine sulfate

Cat. No.: HY-101238

Agmatine sulfate exerts modulatory action at multiple molecular targets, such as neurotransmitter systems, ion channels and nitric oxide synthesis. It is an endogenous agonist at imidazoline receptor and a NO synthase

Purity: >98.0%

Clinical Data: No Development Reported 10 mM × 1 mL, 100 mg, 500 mg, 1 g Size:

Allantoin

(5-Ureidohydantoin)

Allantoin is a skin conditioning agent that promotes healthy skin, stimulates new and healthy tissue growth.

Cat. No.: HY-N0543

99.85% Purity: Clinical Data: Launched

Size: 10 mM × 1 mL, 100 mg

Efaroxan hydrochloride

Efaroxan hydrochloride is a potent, selective and orally active α2-adrenoceptor antagonist, with antidiabetic activity. Efaroxan hydrochloride is a selective I1-Imidazoline receptor antagonist. Efaroxan hydrochloride can be used for the research of cardiovascular disease.

H-CI

Cat. No.: HY-B1416A

Purity:

Clinical Data: No Development Reported 5 mg, 10 mg, 50 mg, 100 mg

Harmane

Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC_{so} =30 nM) over α 2-adrenoceptor

 $(IC_{50}=18 \mu M).$

Purity: 99.81%

Clinical Data: No Development Reported

100 mg

Cat. No.: HY-101392

Harmane-d1

Cat. No.: HY-101392S

Harmane-d1 is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations.

Purity: 95.19%

Clinical Data: No Development Reported

Size: 5 mg, 10 mg

Harmane-d2

Harmane-d2 is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations.

Cat. No.: HY-101392S1

>98% Purity:

Clinical Data: No Development Reported

Size: 1 mg, 5 mg

Idazoxan hydrochloride

(RX 781094 hydrochloride)

Idazoxan hydrochloride (RX 781094 hydrochloride) is an α_3 -adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like drugs (IMs).

H-CI

Cat. No.: HY-14561A

Purity: 98.21%

Clinical Data: No Development Reported 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Size

Idazoxan-d4 hydrochloride

(RX 781094-d4 hydrochloride)

Idazoxan-d4 (RX 781094-d4) hydrochloride is the deuterium labeled Idazoxan hydrochloride.

Cat. No.: HY-14561AS

>98% Purity:

Clinical Data: No Development Reported

Size: 1 mg, 10 mg

Moxonidine

(BDF5895) Cat. No.: HY-B0374

Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent. Target: I1-R Moxonidine is a centrally acting antihypertensive agent.

Purity: 99.72% Clinical Data: Launched

10 mM × 1 mL, 100 mg Size

Moxonidine hydrochloride

(BDF5895 hydrochloride)

Moxonidine Hydrochloride is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent. Target: I1-R Moxonidine Hydrochloride is a centrally acting antihypertensive agent.

>98% Clinical Data: Launched 1 mg, 5 mg

Cat. No.: HY-B0374A

Moxonidine-d4

Moxonidine-d4 (BDF5895-d4) is the deuterium labeled Moxonidine. Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.

Cat. No.: HY-B0374S

Purity: > 98%

Clinical Data:

Size: 1 mg, 10 mg

Rilmenidine

Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy.

N N N

Cat. No.: HY-100490

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rilmenidine hemifumarate

Cat. No.: HY-100490A

Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective II imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy.

Purity: 99.82% Clinical Data: Launched Size: 5 mg, 10 mg

0.5 HO OH

Rilmenidine-d4

Cat. No.: HY-100490S

Rilmenidine-d4 is the deuterium labeled Rilmenidine. Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy.

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg

Rilmenidine phosphate

Cat. No.: HY-100490B

Rilmenidine phosphate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine phosphate is an alpha 2-adrenoceptor agonist. Rilmenidine phosphate induces autophagy.

Purity: ≥98.0% Clinical Data: Launched

Size: 5 mg, 10 mg, 25 mg